TransCon IL-2 Β/γ Alone or in Combination with Pembrolizumab, Standard of Care Chemotherapy or TransCon TLR7/8 Agonist in Advanced/metastatic Solid Tumors: Updated Results of the Phase 1/2 IL Believe Study.
JOURNAL OF CLINICAL ONCOLOGY（2024）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要